- Home
- VRCA vs COEP Comparison
VRCA vs COEP Comparison
Compare VRCA & COEP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VRCA
- COEP
- Stock Information
- Founded
- VRCA 2013
- COEP 2017
- Country
- VRCA United States
- COEP United States
- Employees
- VRCA N/A
- COEP N/A
- Industry
- VRCA Biotechnology: Pharmaceutical Preparations
- COEP Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- VRCA Health Care
- COEP Health Care
- Exchange
- VRCA Nasdaq
- COEP Nasdaq
- Market Cap
- VRCA 43.0M
- COEP 39.0M
- IPO Year
- VRCA 2018
- COEP N/A
- Fundamental
- Price
- VRCA $0.42
- COEP $8.76
- Analyst Decision
- VRCA Hold
- COEP
- Analyst Count
- VRCA 5
- COEP 0
- Target Price
- VRCA $6.00
- COEP N/A
- AVG Volume (30 Days)
- VRCA 243.3K
- COEP 101.7K
- Earning Date
- VRCA 05-13-2025
- COEP 05-20-2025
- Dividend Yield
- VRCA N/A
- COEP N/A
- EPS Growth
- VRCA N/A
- COEP N/A
- EPS
- VRCA N/A
- COEP N/A
- Revenue
- VRCA $7,566,000.00
- COEP N/A
- Revenue This Year
- VRCA $127.58
- COEP N/A
- Revenue Next Year
- VRCA $88.06
- COEP N/A
- P/E Ratio
- VRCA N/A
- COEP N/A
- Revenue Growth
- VRCA 47.66
- COEP N/A
- 52 Week Low
- VRCA $0.38
- COEP $2.31
- 52 Week High
- VRCA $11.41
- COEP $13.70
- Technical
- Relative Strength Index (RSI)
- VRCA 39.53
- COEP 46.43
- Support Level
- VRCA $0.45
- COEP $7.81
- Resistance Level
- VRCA $0.48
- COEP $11.17
- Average True Range (ATR)
- VRCA 0.04
- COEP 1.43
- MACD
- VRCA -0.00
- COEP -0.14
- Stochastic Oscillator
- VRCA 22.13
- COEP 40.06
About VRCA Verrica Pharmaceuticals Inc.
Verrica Pharmaceuticals Inc is a dermatology therapeutics company engaged in the development and commercialization of novel treatments that provide a meaningful benefit for people living with skin diseases. Its product candidate, VP-102, is developed for the treatment of molluscum contagiosum, or molluscum, a contagious and pediatric viral skin disease, and common warts.
About COEP Coeptis Therapeutics Holdings Inc.
Coeptis Therapeutics Holdings Inc is a biopharmaceutical company developing cell therapy platforms for patients with cancer. The company's product portfolio consists of multi-antigen CAR T technology licensed from the University of Pittsburgh (SNAP-CAR), a cell therapy technology (CD38-GEAR-NK), and an in vitro diagnostic (CD38-Diagnostic) targeting CD38-related cancers, which the company is developing with VyGen-Bio and medical researchers at the Karolinska Institutet.